Profile
Company facts
- Exchange
- SHG
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CNE000000WF9
- Market cap
- 25B
- P/E ratio
- 32.71
- Analyst target
- 17.4667
- Dividend yield
- 1.6%
- Beta
- 0.22
About
About Beijing Tiantan Biological Products Co., Ltd
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationally. Its products include human serum albumin; intravenous human immunoglobulin; rabies immunoglobulin; tetanus immunoglobulin; hepatitis B immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex concentrate; lyophilized intravenous hepatitis B immunoglobulin; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for injection; and other blood products. The company was founded in 1966 and is headquartered in Beijing, China.
Visit company website
5 years, 5 months ago
Beijing Tiantan Biological Products Co., Ltd is currently in a long term uptrend where the price is trading 3.7% above its 200 day moving average.
From a valuation standpoint, the stock is 24.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 12.0.
Beijing Tiantan Biological Products Co., Ltd's total revenue rose by 12.7% to $1B since the same quarter in the previous year.
Its net income has increased by 23.0% to $213M since the same quarter in the previous year.
Finally, its free cash flow fell by 61.6% to $34M since the same quarter in the previous year.
Based on the above factors, Beijing Tiantan Biological Products Co., Ltd gets an overall score of 3/5.